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Background:
Neuropathic pain is a chronic pain due to disorder in the peripheral or central nervous system with different 
pathophysiological mechanisms. Current treatments are not effective. Analgesic drugs combined can reduce 
pain intensity and side effects. Here, we studied the analgesic effect of nimesulide, nefopam, and morphine 
with different mechanisms of action alone and in combination with other drugs in chronic constriction injury 
(CCI) model of neuropathic pain.
Methods: 
Male Wistar rats (n = 8) weighing 150−200 g were divided into 3 different groups: 1- Saline-treated CCI 
group, 2- Saline-treated sham group, and 3- Drug-treated CCI groups. Nimesulide (1.25, 2.5, and 5 mg/kg), 
nefopam (10, 20, and 30 mg/kg), and morphine (1, 3, and 5 mg/kg) were injected 30 minutes before surgery 
and continued daily to day 14 post-ligation. In the combination strategy, a nonanalgesic dose of drugs was used 
in combination such as nefopam + morphine, nefopam + nimesulide, and nimesulide ＋ morphine. Von Frey 
filaments for mechanical allodynia and acetone test for cold allodynia were, respectively, used as pain behavioral 
tests. Experiments were performed on day 0 (before surgery) and days 1, 3, 5, 7,10, and 14 post injury. 
Results: 
Nefopam (30 mg/kg) and nimesulide (5 mg/kg) blocked mechanical and thermal allodynia; the analgesic 
effects of morphine (5 mg/kg) lasted for 7 days. Allodynia was completely inhibited in combination with 
nonanalgesic doses of nefopam (10 mg/kg), nimesulide (1.25 mg/kg), and morphine (3 mg/kg).
Conclusions:
It seems that analgesic drugs used in combination, could effectively reduce pain behavior with reduced 
adverse effects. (Korean J Pain 2012; 25: 7-15)
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INTRODUCTION
Neuropathic pain can arise as a result of damage to 
the peripheral or central nervous system and includes a 
variety of conditions that differ in etiology as well as 
location. Sensory abnormalities which manifest as allodynia 
(pain evoked by normally non-noxious stimuli), and hyper-
algesia (an increased response to a noxious stimuli) are 
routinely observed in human neuropathic pain conditions 
as well as in relevant animal models [1-3]. Many drugs 
have tried to reduce neuropathic pain but the underlying 
mechanisms of neuropathic pain are multiple and complex; 
therefore, treatment and management of this distressing 
condition are suggesting the use of more than one type 
of medication [4]. 
Among analgesics, morphine is a widely used drug in 
the treatment of moderate to severe pain. There is consid-
erable controversy for opioid analgesics to treat chronic 
pain [3]. For example, opioids were reported to be ineffec-
tive in some patients with neuropathic pain [5], whereas 
other observations suggest that opioids are effective in at-
tenuating neuropathic pain [6,7]. However, respiratory de-
pression, sedation, constipation and tolerance are the 
most important side effects of opioids which limit their 
clinical application in neuropathic pain [8]. 
Non Steroidal Anti Inflammatory Drugs (NSAIDs) are 
used in the management of chronic, inflammatory and 
postoperative pain [9]. Nimesulide, a highly selective COX-2 
inhibitor, has induced analgesia compared to other NSAIDs 
such as celecoxib, indomethacin, and naproxen in painful 
osteoarthritis and some other conditions [10-12]. The effi-
cacy of nimesulide in neuropathic pain is not well 
established. However the most common side effects of 
NSAIDs are gastrointestinal troubles, hepatotoxicity, and 
nephrotoxicity [13]. 
Nefopam, a nonopioid drug with a mechanism different 
from other analgesics is a centrally acting agent [14]. The 
antinociceptive effect of nefopam has been shown in ani-
mal models of acute and chronic pain and in human. 
Nefopam reduced pain in some behavioral tests (the hot 
plate [15], formalin [16]; carrageenan and incision induced 
thermal hyperalgesia tests [17]). Moreover, many clinical 
studies have evaluated the analgesic efficacy of nefopam 
in postoperative pain [18,19]. Nefopam has shown a pro-
tective analgesic effect when used in single doses in the 
CCI model of chronic neuropathic pain [20]. However, as 
for other analgesic drugs, some unpleasant adverse effects 
of nefopam including dizziness, headache, nausea, vomit-
ing, and sweating are consistent with its central mecha-
nism of action [14,21].
Multidrug therapy (MDT) has been widely accepted in 
the pharmacological management of a wide variety of 
complex chronic medical disorders including hypertension, 
HIV, cancer, and pain conditions like postoperative pain 
and neuropathic pain. The use of drug combinations from 
different pharmacological classes is expected to improve 
analgesia and to decrease the incidence and/or severity of 
the side effects of each drug [22]. 
From this perspective, our study was designed to eval-
uate the antiallodynic effects of different pharmacological 
classes of analgesic drugs. In this regards, we used an 
opioid drug (morphine), a highly selective COX-2 inhibitor 
(nimesulide), and a nonopioid drug (nefopam) in a dose- 
dependent manner alone, and in combination in chronic 
constriction injury (CCI) model of neuropathic pain in rats.
MATERIALS AND METHODS
1. Animals
Experiments were carried out on male Wistar rats 
(150-200 g) that were housed one rat per cage and placed 
under a 12 hour light/dark cycle in a temperature-controlled 
room (22 ± 1oC). Animals had free access to food and 
water. Rats were divided randomly into several experi-
mental groups, each made-up of 8 animals. All experi-
ments followed the IASP guidelines on ethical standards for 
investigation of experimental pain in animals [23]. The an-
imals were allowed to habituate to the housing facilities for 
one week before the experiments began. Behavioral studies 
were performed in a quiet room between 9:00 to 11:00 AM. 
Efforts were made to limit distress and to use the minimum 
number of animals necessary to achieve statistical signi-
ficance.
2. Surgery
We used the CCI model of neuropathic pain [24]. The 
surgical procedure was performed under ketamine (60 mg/kg) 
and xylazine (10 mg/kg) anaesthesia. The left sciatic nerve 
was exposed and 4 loose chromic gut ligatures were placed 
around the nerve proximal to the trifurcation. The distance 
between the two adjacent ligatures was 1 mm. The wound 
was irrigated with saline (0.9%) and closed in two layers 
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with 4-0 silk (facial plane) and surgical skin staples. In 
the saline-treated sham group, rats underwent the same 
surgical procedure except for the ligation. 
3. Drug preparation
Nimesulide (Sigma, USA) was prepared as suspension 
in saline 0.9%. Nefopam (Biocodex Laboratories, France) 
and morphine (Sigma, USA) were dissolved in saline 0.9%. 
Ketamine hydrochloride (Sigma, USA) and Xylazine hydro-
chloride (Sigma, USA) were used for the anesthesia. All 
drugs were injected by the intra-peritoneal (IP) route.
4. Drug administration
Animals were randomly divided into three experimental 
groups: 1- Saline-treated CCI group, 2- Saline-treated 
sham group, and 3- Drug-treated CCI groups. In one 
study, animals received morphine (1, 3, and 5 mg/kg) [25], 
nefopam (10, 20, and 30 mg/kg) [20], and nimesulide (1.25, 
2.5, and 5 mg/kg) [10]. In another study, a nonanalgesic 
dose of each drug was selected and used in combination 
as follows: “nefopam-nimesulide”, “nefopam-morphine”, 
and “morphine-nimesulide”. Drugs were injected 30 minutes 
before surgery and continued daily to day 14 post-ligation. 
All behavioral tests were recorded on day 0 (control day) 
before the surgery and on days 1, 3, 5, 7, 10, and 14 
post-nerve injury. The order of pain testing was mechan-
ical and cold allodynia, respectively (the interval between 
each test was 30 minutes). 
5. Behavioral tests and experimental design
The sciatic nerve territory (mid-plantar hind paw) was 
tested for sensitivity to noxious and innocuous stimuli using 
standard behavioural assays done sequentially at several 
intervals up to 14 days following surgery. Animals were 
acclimated to the testing chambers for 30 min prior to 
testing. Mechanical and cold allodynia were evaluated in 
the animals.
1) Mechanical allodynia: Mechanical sensitivity to non- 
noxious stimuli was measured with a set of calibrated nylon 
monofilaments (Stoelting, USA). The von Frey methodology 
was used to assess the sensitivity of the skin to tactile 
stimulation. Von Frey filaments are calibrated to have a 
characteristic bending force when pressure is applied. Each 
rat was placed under a transparent Plexiglas cage on an 
elevated metal screen surface with 1 cm mesh openings. 
Increasing strengths of von Frey filaments were applied 
sequentially to the plantar surface of the left hind paw of 
each animal. The minimum paw withdrawal threshold 
(PWT), defined as the minimum gram strength eliciting two 
sequential responses with 3 min intervals between them 
(withdrawal from pressure), was recorded for the left paw. 
The intensity of the mechanical stimulation increased from 
2 to 60 g in a graded manner using successively greater 
diameter filaments until the hind paw was withdrawn. For 
successive tests, the placement of these stimuli was varied 
slightly from one trial to the next to avoid sensitization of 
the hind paw [26] .
2) Cold allodynia: The acetone test [27] was used to deter-
mine the reactivity to an acetone stimulus. Rats were 
placed under a transparent Plexiglas cage, as described 
previously, and an acetone bubble was formed at the end 
of a piece of small polyethylene tubing that was connected 
to a syringe; then, the bubble was lightly touched to the 
heel. The acetone was applied 5 times with an interval of 
1 min between application, and the number of paw lifts 
from surface was the response measured. The response 
was calculated as the percent of paw withdrawal frequency 
(%PWF) using the following equation:
(Number of paw withdrawals / 5 trials) × 100.
6. Statistical analysis 
Parametric data were analyzed for significance with 
analysis of variance (ANOVA) followed by a post-hoc 
Tukey's test. Non-parametric data were analyzed with 2 
related samples followed by the Wilcoxon test. In all cases, 
data were shown as the mean ± SEM (standard error) and 
P ＜ 0.05 was considered significant.
RESULTS
1. Dose-dependent effects of nefopam, nimesulide, and 
morphine
1) Response to mechanical allodynia (von Frey Filament 
test): Fig. 1: All saline-treated CCI groups were strongly 
allodynic at the fifth day post-ligation (P ＜ 0.001) com-
pared to the control day; this effect was sustained until 
the end of the study. On the contrary, the saline-treated 
sham group did not show any mechanical allodynia for the 
duration of the experimental period as compared to the 
pre-surgery day. During the period of the study, in the 
drug-treated CCI groups, nefopam reduced mechanical 
allodynia for 20 and 30 mg/kg doses, but not for a 10 mg/kg 
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Fig. 1. Paw withdrawal threshold in response to von Frey 
filaments before and at several time points after surgery 
in the saline-treated CCI group, saline-treated sham group, 
and drug-treated CCI group. Nefopam (10, 20, and 30 
mg/kg (A)), Nimesulide (1.25, 2.5, and 5 mg/kg (B)), mor-
phine (1, 3, and 5 mg/kg (C)) were injected i.p. Results 
are expressed as the mean ± SEM of 8 animals per group. 
Nef: Nefopam, Nim: Nimesulide, Mor: Morphine. Asterisks 
indicate a significant difference between post surgery days 
compared with day 0 (*P ＜ 0.05, †P ＜ 0.01, ‡P < 0.001).
dose (P ＜ 0.05) (Fig. 1A); anti-allodynic effect of nimesu-
lide was seen for 2.5 and 5 mg/kg doses, but not for a 
1.25 mg/kg dose (P ＜ 0.05) (Fig. 1B); morphine (5 mg/kg) 
decreased the tactile allodynia until day 7, but not for 1 
and 3 mg/kg doses (P ＜ 0.05) (Fig. 1C).
2) Response to cold allodynia (Acetone test): Fig. 2: In the 
saline-treated CCI group, a significant difference in pain 
behavior (P ＜ 0.001) was seen on the fifth day post- 
injury compared to day 0; this effect continued until the 
end of the study. However, cold allodynia was not observed 
in the saline-treated sham group. In the drug-treated CCI 
group, nefopam reduced cold allodynia for 20 and 30 
mg/kg doses, but not for a 10 mg/kg dose (P ＜ 0.05) 
(Fig. 2A); nimesulide produced an antiallodynic effect for 
2.5 and 5 mg/kg doses but not for a 1.25 mg/kg dose 
(P ＜ 0.01) (Fig. 2B); the antiallodynic effect of morphine 
(5 mg/kg) lasted for 5 days, but not for the 1 and 3mg/kg 
doses (P ＜ 0.01) (Fig. 2C). 
2. The effect of combination therapy 
1) Response to mechanical allodynia (von Frey Filament): 
Fig. 3A: Pain behavior was not seen in all drug-treated 
CCI groups when used in combination [(morphine 3 mg/kg 
＋ nefopam 10 mg/kg), (morphine 3 mg/kg ＋ nimesulide 
1.25 mg/kg), (nimesulide 1.25 mg/kg ＋ nefopam 10 mg/kg)] 
during the experimental period compared to day 0 
presurgery.
2) Response to cold allodynia (Acetone test): Fig. 3B: All 
drug-treated CCI groups [(morphine 3 mg/kg ＋ nefopam 
10 mg/kg), (morphine 3 mg/kg ＋ nimesulide 1.25 mg/kg), 
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Fig. 2. The frequency of paw withdrawal in response to 
acetone before and at several time points after surgery in 
the saline-treated CCI group, saline-treated sham group, 
and drug-treated CCI group. Nefopam (10, 20, and 30 
mg/kg (A)), Nimesulide (1.25, 2.5, and 5 mg/kg (B)), mor-
phine (1, 3, and 5 mg/kg (C)) were injected i.p. Results 
are expressed as the mean ± SEM of 8 animals per group. 
Nef: Nefopam, Nim: Nimesulide, Mor: Morphine. Asterisks 
indicate a significant difference between post surgery days 
compared with day 0 (*P ＜ 0.05, †P ＜ 0.01, ‡P ＜ 0.001).
(nimesulide 1.25 mg/kg ＋ nefopam 10 mg/kg) did not pro-
duce pain behavior compared to day 0 presurgery when 
used in combination. 
 DISCUSSION 
In this study, the analgesic effects of drugs with diffe-
rent mechanisms of action (nimesulide, nefopam, and 
morphine) were investigated alone and in combination, in 
a rat model of neuropathic pain. We used the CCI model 
of nerve injury because it has an inflammatory and a 
nerve injury components which are reported to mimic types 
of neuropathic pain found in humans [24]. The manage-
ment of neuropathic pain remains a major clinical challenge. 
This is in part due to an inadequate understanding of the 
mechanisms involved in the disease etiology, but also a re-
sult of the relative absence of clinically effective treat-
ments [28].
Opioids are the drugs of choice for the treatment of 
moderate to severe pain, however, a large number of clin-
ical studies have reported that opioids, particularly mor-
phine, had weak analgesic efficacy in neuropathic pain in 
humans [29]. In our research, lower doses of morphine did 
not reduce mechanical and cold allodynia during the ex-
perimental period. The antiallodynic effect of morphine 
used at a high dose lasted for a few days. However, it 
seems that the reduced analgesic effect of morphine may 
be due to the tolerance of its analgesic effects. There are 
some controversies about the relative efficacy of opiate 
analgesics against neuropathic pain in clinical and ex-
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Fig. 3. Paw withdrawal threshold in response to von Frey filaments (A) and the frequency of paw withdrawal in response 
to acetone (B) before and at several time points after surgery in saline-treated CCI group, saline-treated sham group and
drug-treated CCI groups in combination: (morphine 3 mg/kg ＋ nefopam 10 mg/kg, morphine 3 mg/kg ＋ nimesulide 1.25
mg/kg, nimesulide 1.25 mg/kg ＋ nefopam 10 mg/kg) were injected i.p. Results are expressed as the mean ± SEM of
8 animals per group. Nef: Nefopam, Nim: Nimesulide, Mor: Morphine. Asterisks indicate a significant difference between
post surgery days compared with day 0 (*P ＜ 0.01, †P ＜ 0.001).
perimental researches [30]. 
Pre-emptive analgesia can provide an effective treat-
ment which prevents the establishment of altered central 
processing, amplifying post-operative pain. Evidence showed 
that pre-emptive injection of nefopam and nimesulide had 
produced effective analgesia [20,31], while morphine pro-
duced a slight antiallodynic effect in the CCI model of neu-
ropathic pain [29].
Nefopam, a nonopioid analgesic drug, can produce 
analgesia in animals and humans. It was reported that in 
CCI model of neuropathic pain, a single dose of nefopam, 
significantly reduced pain behavior. Moreover, it was 
shown that nefopam has preventive analgesic effects [20]. 
Acute administration of nefopam (intraperitoneal, sub-
cutaneous, and oral) exhibited a dose-dependent attenu-
ation of pain behavior in hot plate and plantar tests [15]. 
In our experiment, high doses of nefopam showed pain re-
ducing effects, which is consistent with previous studies 
[15,20]. Although a single dose of nefopam (30 mg/kg) re-
duced pain behavior in the CCI model of neuropathic pain 
[20], we observed that daily administration of nefopam (30 
& 20 mg/kg) showed analgesic effects. It seems that 
chronic administration of nefopam could probably attenu-
ate pain behavior in a dose-dependent manner. However, 
we noticed a hyperexcitability state, which was seen when 
a high dose of nefopam (30 mg/kg) was injected into the 
rats. This effect was transient and disappeared after 30 
minutes of drug administration.
Nimesulide, a highly selective COX-2 inhibitor, inhibits 
PGE2 and nitric oxide production and modulates neural 
transmission at the level of the dorsal horn [31]. Among 
numerous properties of nimesulide, decreased tumor ne-
crosis factor α (TNF-α) and neutrophil accumulation in the 
inflammatory exudates were reported [9]. Nimesulide has 
a relatively rapid onset of antihyperalgesic effects in hu-
mans when compared with well-established NSAIDs such 
as diclofenac, celecoxib, and rofecoxib. It was shown that 
nimesulide can properly reduce pain and inflammation in 
formalin and other inflammatory tests [10]. Our results 
show that moderate and high doses of nimesulide reduced 
mechanical and cold allodynia, which are consistent with 
the results of previous works [9,10,31]
The use of multiple drug therapy is common in clinical 
and experimental conditions, including neuropathic pain. 
The rationale behind drug combination is that there are 
multiple mechanisms involved in generating chronic pain 
[22]. In one study, patients with diabetic neuropathy and 
post herpetic neuralgia were treated with a combination of 
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gabapentin and morphine, compared with either drug alone 
or with a placebo. The combination of gabapentin and 
morphine provided better pain relief at smaller doses for 
each drug [32]. It seems that it is unlikely that a single 
drug can effectively reduce pain and treat neuropathic pain.
According to our results, nonanalgesic doses of nefo-
pam, nimesulide, and morphine were selected. Co-admin-
istration of these drugs exhibited antiallodynic effects.
Few experimental studies have investigated the effects 
of the co-administration of nefopam with morphine or 
opioid agonists. In one study, carrageenan-induced tactile 
allodynia test, co-administration of weak analgesic doses 
of nefopam with moderate analgesic doses of morphine 
significantly reduced allodynia. Moreover, co-administration 
of nonanalgesic doses of nefopam with a nonanalgesic 
doses of morphine completely inhibited carrageenan- or 
incision-induced thermal hyperalgesia [17]. In clinical stud-
ies concerning abdominal, urogenital, orthopedic surgery, 
and hepatic resection, nefopam has been shown to reduce 
morphine consumption [18,19]. Enhancement of morphine 
antinociception by other monoamine reuptake inhibitors 
has been shown with clomipramine, amitriptyline, and 
fluoxetine in animals [33,34]. We can conclude that, by in-
hibiting monoamine reuptake, these drugs as well as nefo-
pam can induce an increase in noradrenaline, serotonin, 
and/or dopamine levels in the central nervous system; 
therefore, the enhancement of morphine-associated anti-
nociception can thus be rationalized. 
In a recent study, the antinociceptive characteristics 
of the combination of nefopam and paracetamol were 
evaluated using four different animal models of pain. Data 
analysis revealed that, drug combination significantly 
blocked allodynia in the carrageenan test, in the inflam-
matory phase in the formalin test, in thermal hyperalgesia 
in the incision model of postoperative pain, and in abdomi-
nal writhes in the acetic acid test [35]. Evidence showed 
an interaction in co-administration of nefopam and keto-
profen in postoperative pain, which increases their an-
algesic efficacy and reduces their side effects [36]. In our 
research, we found that the combination of nefopam and 
nimesulide can reduce pain behavior, which is consistent 
with the above mentioned studies [35,36]. As stated before, 
NSAIDs may exert their antinociceptive activity by inhibi-
tion of prostaglandins biosynthesis and through other 
complex mechanisms. These include modulation by endog-
enous opioids and cholinergic, serotonergic, and nora-
drenergic mechanisms [37,38]. Experimental studies in an-
imal models have demonstrated that nimesulide inhibits 
COX-2 and nitric oxide synthetase (NOS) in the spinal cord 
confirming the central action of the drug. Therefore, the 
antinociceptive activity of nimesulide partly involves the 
inhibition of inflammation, a mechanism of action different 
from that of the other analgesic drugs acting centrally like 
nefopam [31,39]. 
Several combinations of opioids and anti-inflammatory 
drugs have been examined in various models of pain and 
inflammation. For example, in one study, the combination 
of morphine and diclofenac has been shown to be effective 
in a model of acute inflammatory pain [40]. A synergistic 
antiallodynic effect of spinal morphine administered with 
ketorolac in nerve injured rats has also been reported [41]. 
Recently, it has been shown that the antinociceptive activity 
of morphine combined with different NSAIDs (including ni-
mesulide, meloxicam, diclofenac, naproxen, piroxicam, 
parecoxib, and ketoprofen) induced a synergistic interaction 
in the mice model of visceral acute pain [42].
Considering these data, in our study, we found that 
a combination of nonanalgesic doses of nefopam, mor-
phine, and nimesulide could reduce effectively mechanical 
and cold allodynia. Our data are consistent with previous 
works on combination therapy in an attempt to reduce pain 
behavior [40-42].
In conclusion, our results show that nefopam, mor-
phine, and nimesulide used pre-emptively reduced pain in 
a dose-dependent manner throughout the experiments. 
Although the analgesic effect of morphine was not com-
parable to nefopam and nimesulide, we found an effective 
response for combination therapy in reducing pain beha-
viors. Further evaluations are needed to establish the type 
of interaction between these drugs in combination therapy 
in the CCI model of neuropathic pain. 
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